Gemcitabine

[SDL] Gemcitabine Infusion 200 mg, 1000 mg, 2000 mg

[MSHL] Gemcitabine Vial 200 mg, 1 g, 2 g

1. For cancer treatment.

Legend

This section shows the following:

• Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs

• Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List

• Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

03/05/2017 Gemcitabine for the treatment of cancer

Following an evaluation of gemcitabine for advanced bladder cancer and non-small-cell lung cancer, the MOH Drug Advisory Committee has recommended to list gemcitabine 1g, 2g and 200mg on the MOH Standard Drug List (SDL) in view of its comparable clinical efficacy and safety to other standard chemotherapy regimens and low annual cost of subsidy.

[R] This recommendation means that subsidies will apply to gemcitabine for the indications registered in Singapore:

• First-line treatment of locally advanced or metastatic non-small cell lung cancer in combination with cisplatin and palliative treatment of adult patients with locally advanced or metastatic non-small cell lung cancer;

• Treatment of adult patients with locally advanced or metastatic adenocarcinoma of the pancreas;

• Treatment of advanced bladder cancer in combination with cisplatin;

• Treatment of unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant or neoadjuvant chemotherapy in combination with paclitaxel.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration